Physician profile
William J Harmon
NPI 1104806207
$9,833.88
in general payments reported to CMS, 2019-2025
33 companies · $2,416 in 2025
The $2,416 reported for 2025 was more than what 83% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,569 · 2020: $73.62 · 2021: $142 · 2022: $1,243 · 2023: $394 · 2024: $3,997 · 2025: $2,416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,360 · Consulting Fee: $1,388 · Honoraria: $1,000 · Travel and Lodging: $960 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,360.23 |
| Consulting Fee | $1,387.50 |
| Honoraria | $1,000.00 |
| Travel and Lodging | $960.00 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sn Holdings, LLC | $2,617.00 | 2021-2024 | |
| Janssen Biotech, INC. | $2,215.65 | 2019-2025 | Erleada, Akeega |
| Intuitive Surgical, INC. | $1,318.47 | 2019-2022 | |
| Myriad Genetic Laboratories, INC. | $900.00 | 2022 | |
| Merck Sharp & Dohme LLC | $454.45 | 2022-2025 | Lynparza, Keytruda, Welireg |
| Blue Earth Diagnostics | $371.91 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $329.90 | 2024-2025 | |
| Lazarus 3d | $239.18 | 2024 | Pre-Sure |
| Boston Scientific Corporation | $197.38 | 2019-2023 | Lithovue |
| Astellas Pharma US INC | $148.49 | 2019-2023 | Myrbetriq |
| Calyxo, INC. | $141.67 | 2024 | Cvac Aspiration System |
| Sumitomo Pharma America, INC. | $127.13 | 2023-2025 | Orgovyx, Gemtesa |
| Coloplast Corp | $109.83 | 2024 | |
| Medtronic, INC. | $106.08 | 2024-2025 | Interstim |
| Pfizer INC. | $63.13 | 2023-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $53.23 | 2024 | Axonics |
| Myovant Sciences INC. | $51.01 | 2022 | |
| Dendreon Pharmaceuticals LLC | $46.44 | 2020-2024 | Provenge |
| Antares Pharma, INC. | $42.52 | 2019-2024 | Xyosted |
| Dornier Medtech America, INC | $41.52 | 2020 | |
| Foundation Medicine, INC. | $38.71 | 2023 | Foundationone Cdx |
| Astrazeneca Pharmaceuticals LP | $29.79 | 2024 | Lynparza |
| Procept Biorobotics Corporation | $29.21 | 2025 | |
| Corcept Therapeutics | $28.25 | 2025 | Korlym |
| Photocure INC | $25.02 | 2019 | |
| Verity Pharmaceuticals INC. | $23.38 | 2022 | |
| Olympus America INC. | $17.34 | 2022 | |
| Halozyme INC | $17.26 | 2023 | |
| Tolmar, INC. | $15.94 | 2023 | |
| Tolmar Pharmaceuticals, INC. | $14.33 | 2020 | |
| Travere Therapeutics, INC. | $12.80 | 2019 | |
| Edap Technomed INC | $6.86 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$340,124.48 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Harmon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.